Comparative Pharmacology
Head-to-head clinical analysis: CIPRO XR versus PROQUIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO XR versus PROQUIN XR.
CIPRO XR vs PROQUIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
500 mg to 1000 mg orally once daily for 7 to 14 days; extended-release tablet must be swallowed whole and administered with food.
500 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, allowing twice-daily dosing; due to extended-release formulation, ciprofloxacin is released over 24 hours.
Terminal elimination half-life is approximately 10-14 hours in patients with normal renal function (CrCl >80 mL/min). Extended half-life may occur in renal impairment, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for approximately 40-50% of the dose; hepatic metabolism (glucuronidation, sulfation) produces active metabolites, and biliary/fecal elimination (via feces) accounts for 20-35% of the dose.
Primarily renal excretion of unchanged drug (~60-80%) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 20-35%, with a small portion as metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic